#valsartan

CAS NO 137862-53-4 (VALSARTAN) | Verdantpharma

In modern medicine, the management of cardiovascular diseases has become increasingly advanced, with several classes of drugs designed to control blood pressure and improve heart health. One such important compound is Valsartan, identified by CAS No. 137862-53-4. This compound belongs to a class of medications known as angiotensin II receptor blockers (ARBs) and plays a crucial role in treating hypertension and related conditions.

Chemical Identity and Properties

Valsartan is a synthetic, non-peptide compound with the molecular formula C₂₄H₂₉N₅O₃ and a molecular weight of approximately 435.5 g/mol. It appears as a white to slightly off-white powder and exhibits moderate solubility in organic solvents such as DMSO. Its melting point typically falls in the range of 116–117°C, indicating good thermal stability for pharmaceutical applications.

Structurally, valsartan contains a biphenyl-tetrazole moiety, which is characteristic of many ARBs. This structure is critical for its biological activity, allowing it to selectively interact with angiotensin II receptors in the body.

Pharmacological Classification

Valsartan belongs to the angiotensin II receptor blocker (ARB) class. These drugs are widely used in cardiovascular therapy due to their ability to regulate blood pressure without some of the side effects associated with older drug classes. 

Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs such as valsartan do not interfere with bradykinin metabolism. This distinction is important because it reduces the likelihood of side effects like persistent cough, which are commonly seen with ACE inhibitors.

Mechanism of Action

The therapeutic action of valsartan is based on its ability to selectively block the angiotensin II type 1 (AT1) receptor. Angiotensin II is a hormone that causes blood vessels to constrict and stimulates the release of aldosterone, leading to increased blood pressure.

By blocking AT1 receptors, valsartan:

Prevents vasoconstriction (narrowing of blood vessels)

Reduces aldosterone secretion

Promotes vasodilation (widening of blood vessels)

Helps maintain electrolyte and fluid balance

This selective inhibition leads to a significant reduction in blood pressure without affecting heart rate or causing rebound hypertension upon discontinuation.

Additionally, valsartan does not inhibit ACE or renin activity, making it a targeted and efficient antihypertensive agent.

Therapeutic Uses

Valsartan is widely used in the treatment of various cardiovascular conditions, including:

1. Hypertension

It is commonly prescribed for managing mild to moderate high blood pressure. By lowering vascular resistance, valsartan helps reduce strain on the heart and arteries.

2. Heart Failure

Valsartan improves cardiac function in patients with heart failure by reducing afterload and improving blood circulation.

3. Post-Myocardial Infarction Care

Patients recovering from a heart attack benefit from valsartan, as it lowers the risk of cardiovascular mortality and prevents further complications. 

4. Renal Protection

In patients with diabetes or kidney-related hypertension, valsartan can reduce proteinuria and protect kidney function, making it valuable in long-term disease management.

Pharmacokinetics

After oral administration, valsartan begins to show its antihypertensive effects within 2 hours, with peak activity occurring between 4 to 6 hours. The effects can last for up to 24 hours, allowing for once-daily dosing in many cases. 

Maximum therapeutic benefit is typically achieved after 2 to 4 weeks of continuous use, making adherence to prescribed therapy essential for optimal outcomes.

Advantages Over Other Therapies

Valsartan offers several advantages compared to other antihypertensive drugs:

Lower incidence of cough compared to ACE inhibitors

No significant effect on heart rate

Minimal impact on metabolic parameters such as cholesterol, glucose, and triglycerides

Renal protective effects, especially in diabetic patients

These benefits contribute to its widespread use as a first-line treatment option for hypertension and cardiovascular diseases.

Safety and Considerations

While valsartan is generally well tolerated, certain precautions should be considered:

It may cause hypotension (low blood pressure), especially in dehydrated individuals

There is a risk of hyperkalemia (elevated potassium levels), particularly when combined with other medications affecting potassium balance

Patients with renal impairment should be monitored closely

Drug interactions with NSAIDs and other antihypertensive agents may affect efficacy or safety

As with any pharmaceutical compound, appropriate medical supervision is necessary to ensure safe and effective use.

Industrial and Research Relevance

Beyond its clinical use, valsartan (CAS No. 137862-53-4) is also significant in pharmaceutical research and development. It serves as a model compound in studies involving:

Cardiovascular drug design

Receptor-targeted therapies

Structure-activity relationship (SAR) analysis

Its well-characterized mechanism and efficacy make it a valuable reference in medicinal chemistry.

Conclusion

Valsartan, identified by CAS No. 137862-53-4, stands as a cornerstone in the treatment of hypertension and cardiovascular disorders. Its selective mechanism of action, favorable safety profile, and proven clinical efficacy have made it a widely utilized therapeutic agent.

By effectively blocking angiotensin II receptors, valsartan helps regulate blood pressure, protect vital organs, and improve overall cardiovascular health. As research continues to evolve, this compound remains an important example of how targeted pharmacology can lead to better patient outcomes and improved quality of life.

CAS NO 137862-53-4 (VALSARTAN)

When it comes to modern medicine’s efforts to control high blood pressure and protect the heart, Valsartan holds a significant place. Known chemically by its CAS number 137862-53-4, Valsartan is an active pharmaceutical ingredient (API) prescribed globally for treating a range of cardiovascular conditions. But beyond the prescriptions and patient usage, there is intriguing chemistry, history, and pharmacology behind this molecule that makes it worth understanding for students, researchers, and curious minds alike.

What Is a CAS Number and Why It Matters

A CAS (Chemical Abstracts Service) Registry Number is a unique numerical identifier assigned to every chemical described in open scientific literature. In this case:

CAS No. 137862-53-4 refers uniquely to Valsartan — no other compound shares this exact code.

This number is essential in scientific communication because it avoids ambiguity when referring to specific molecules, especially those with long or multiple names.

Chemical Identity of Valsartan

At the molecular level, Valsartan belongs to a class of compounds known as angiotensin II receptor blockers (ARBs). Its chemical structure is defined by:

A biphenyl backbone

A tetrazole ring

Several functional groups that enhance its binding to specific receptors

In simpler terms, Valsartan’s shape and chemical features allow it to interact precisely with certain proteins in the body — a design that isn’t accidental, but rather the result of targeted medicinal chemistry.

How Valsartan Works in the Body

At the heart of its usefulness is Valsartan’s mechanism of action.

Inside the human body, a hormone called angiotensin II causes blood vessels to tighten (constrict), which increases blood pressure. Valsartan works by blocking the angiotensin II type 1 (AT1) receptor. This prevents the hormone from binding effectively, leading to relaxation of blood vessels, reduced resistance, and therefore lower blood pressure.

This mechanism results in two major clinical benefits:

1. Blood Pressure Control

By preventing vasoconstriction, Valsartan helps maintain a healthier range of blood pressure values. This reduces the risk of complications associated with hypertension — including stroke, heart attack, and kidney damage.

2. Heart Protection After Cardiac Events

Valsartan is often prescribed for patients who have experienced heart failure or a previous heart attack. By reducing the strain on the heart, it helps improve cardiac output and can lead to better long-term outcomes.

Medical Uses and Indications

Though the central use of Valsartan is blood pressure regulation, its clinical applications extend further:

Hypertension (High Blood Pressure) Valsartan is widely used as a first-line or add-on therapy for elevated blood pressure.

Heart Failure Management In certain cases, Valsartan helps improve heart function and reduce symptoms of chronic heart failure.

Post-myocardial Infarction Care Patients recovering from heart attacks may benefit from Valsartan’s protective effects on the heart.

Safety Profile & Common Side Effects

Like all medications, Valsartan does not come without side effects. Most side effects are mild, but awareness is key. Commonly reported effects include:

Dizziness

Fatigue

Headache

Digestive issues (e.g., nausea)

More serious but rare effects can include:

Significant drops in blood pressure

Elevated potassium levels (hyperkalemia)

Renal impairment in vulnerable individuals

It’s important to note that safety profiles depend heavily on dosage, co-existing medical conditions, and other medications a person may be taking.

Valuing the Research Behind Valsartan

The existence of a molecule like Valsartan — with its specificity and clinical benefits — is the outcome of decades of pharmaceutical research. Scientists identified critical biological targets (like the AT1 receptor) and designed molecules with complementary shapes and activities. Analyses such as structure-activity relationships (SAR), pharmacokinetic profiling, and receptor binding studies were crucial in bringing this compound from concept to clinical use.

Furthermore, Valsartan’s journey reflects the importance of interdisciplinary science: organic chemistry, pharmacology, physiology, and clinical medicine all played roles in transforming a chemical entity into a therapeutic agent.

Environmental and Quality Considerations

From an industrial and regulatory perspective, the synthesis and distribution of Valsartan require stringent quality controls. Because APIs like Valsartan are ingested by patients worldwide, their purity, stability, and absence of impurities are critically monitored by health authorities.

Additionally, environmental concerns related to pharmaceutical waste and production processes are increasingly part of discussions around large-scale synthesis of chemical APIs — ensuring that environmental releases are minimized and managed responsibly.

Conclusion: More Than Just a Number

While “CAS No. 137862-53-4” may sound like an abstract code reserved for laboratory catalogs, it represents a molecule that has real, measurable impact on human health. Valsartan stands as a testimony to modern medicinal chemistry — a carefully designed compound that interacts with biological systems in a highly specific way.

Introduction

Sacubitril‑Valsartan is an important combination drug (an angiotensin receptor–neprilysin inhibitor, ARNI) used to treat heart failure, particularly in patients with reduced ejection fraction. It merges two active molecules: sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin receptor blocker). Because heart failure is an increasing health burden in India, there is growing demand for reliable access to this medicine.

Suppliers in India for this combination are responsible for active pharmaceutical ingredients (APIs), finished dosage forms (tablets), or both. They need to satisfy regulatory standards, ensure consistent quality, manage patents/IP, and compete on price.

Market Context & Demand

Heart failure prevalence in India is estimated at about 1%, affecting about 8‑10 million individuals.

The cardiology market in India is large; the ARNI segment (Sacubitril‑Valsartan) is growing rapidly. For example, recent estimates put the ARNI market at several hundred crores of INR, growing year over year at high double digits. 

Price is a key concern, since cost of medicines is a barrier to access for many patients. Indian production of generics and lower‑cost formulations plays a big role.

Types of Suppliers in India

Suppliers can be categorized broadly as follows:

API manufacturers: These companies produce the raw chemicals—sacubitril, valsartan, or the combined API. They must meet standards like DMF filings (e.g. USDMF), good manufacturing practices (GMP), and often export to other countries. For instance, there are suppliers in India that offer Sacubitril/Valsartan API with regulatory filings in multiple countries.

Formulation / tablet manufacturers: These convert APIs into finished dosage forms (tablets), packaging, labelling, distribution. They may supply domestically, or act as exporters.

Wholesalers / distributors / trading houses: These act as intermediaries — sourcing from manufacturers, keeping stock, and supplying hospitals, pharmacies, tenders.

Tender / institutional suppliers: Supply via governmental or large‑scale procurement tenders. These often require more stringent quality checks, and sometimes price negotiations.

Regulatory, Patent & IP Concerns

Patents / Exclusivity: Originally, the innovator company held IP rights over the ARNI combination (Entresto or similar brand names). Over time, generic manufacturers have entered many markets; in India, depending on patent expiry, licensing, and court/registry decisions, generic or branded generic versions are available.

Regulatory approvals: Suppliers need to ensure compliance with regulatory bodies (Indian regulatory agencies, as well as foreign authorities if exporting). This includes Good Manufacturing Practices (GMP), stability data, safety/efficacy data, labelling, etc.

Quality standards: APIs should have acceptable purity, stability, and consistency. Finished dosage forms must pass dissolution, bioavailability, and stability tests. Suppliers often need third‑party certifications (WHO‑GMP, ISO, etc.) and need to maintain documentation (e.g. DMF, master file for APIs) especially for export.

Examples & Pricing

There are generic brands launched in India under different brand names with different strengths (e.g. combinations like 50 mg, 100 mg etc.). 

Pricing is variable. As an example, a tablet in one strength was introduced at approx INR 19 for the lowest strength, INR 35 for mid strength, INR 45 for higher strength by one manufacturer.

Suppliers also include smaller pharma companies that supply via trade‑platforms. For example, there are suppliers offering strips of Sacubitril + Valsartan under certain strengths via trade portals, with MOQ (minimum order quantities) and offers for bulk purchasers.

Challenges Faced by Suppliers

When dealing with Sacubitril‑Valsartan, suppliers in India face several challenges:

Patent / legal risk: Even if a patent has expired in one jurisdiction, in others it may still be valid. Also, licensed generics may need to avoid infringing formulations or data exclusivity.

Regulatory hurdles: Ensuring all approvals, safety and efficacy data, stability, compliance with GMP. For export, meeting standards of importing countries (e.g. US FDA, EMA, etc.).

Quality control: Ensuring consistency of raw material purity, avoiding contamination, maintaining shelf life, etc.

Supply chain & manufacturing costs: APIs may need specialized synthesis steps; any break in supply (raw materials, reagents) can disrupt production. Manufacturing equipment must meet high standards, and overheads (power, labour, infrastructure) matter.

Price competition: Many suppliers want to compete on cost, especially for domestic markets or tenders, which can squeeze margins.

Distribution & logistics: Ensuring cold chain if required, appropriate storage, handling, licensing for transportation, especially when distributing to remote areas.

Regulatory pricing and reimbursement: In India, government regulation of drug pricing (e.g. via National Pharmaceutical Pricing Authority) can influence what prices suppliers can charge, especially for essential medicines. Tender processes may demand low prices.

What to Look for in a Good Supplier

If you are someone seeking to procure Sacubitril‑Valsartan (for hospital, pharmacy, export, etc.), here are key criteria to evaluate:

Regulatory certifications & approvals: GMP licence, DMF/CEF status, approvals from regulatory agencies relevant to your market.

Quality of API and finished product: Certificates of analysis, batch‑to‑batch consistency, stability data, bio‑equivalence if applicable.

Capacity & reliability: Ability to deliver required quantities on schedule; robust supply chain.

Pricing transparency: Clear cost breakup, any licensing or IP costs, distribution/transport expenses.

Legal safety: Ensure supplier is not infringing any patent or data exclusivity in your target market. Check that the brand/generic you procure is legally allowed there.

Post‑sales support: Recall management, ability to handle returns, customer service, and handling adverse event reporting.

Packaging & shelf‑life: Especially in tropical climates like much of India, packaging to resist humidity, heat, light; proper labeling; long enough shelf life.

Future Outlook

As the population ages and incidence of heart failure rises (along with comorbidities like hypertension, diabetes), demand for effective treatments like Sacubitril‑Valsartan is likely to increase.

More generic versions will enter the market; as patents expire, this could lead to increased competition and lower prices.

There may be greater emphasis on local manufacturing of both APIs and formulations to reduce import dependency, control cost, and improve access.

Regulatory harmonization (e.g. aligning with international norms) could make Indian suppliers more competitive for export.

Innovation in formulations (e.g. improved delivery, fixed‑dose combinations, patient adherence) might become a differentiator.

Conclusion

India is already home to a number of suppliers of Sacubitril‑Valsartan—both at the API and finished product levels—serving domestic needs and increasingly reaching international markets. For procurers, the key is to ensure that suppliers meet robust quality, regulatory, and IP standards, while also being reliable and cost‑effective.

If you are considering partnering with or sourcing from a supplier, it makes sense to perform due diligence: check their licenses and certificates, sample product quality, verify legal status in your market, and assess their ability to supply consistently. With the right supplier, access to this important heart failure medicine can be broadened, helping many patients who need it.

Sacubitril Valsartan Supplier in India